Healthtech Startups

Fynn is a software platform designed for senior living communities to manage care coordination, staffing, compliance, and resident outcomes. It helps operators consolidate fragmented care data and enable teams to make proactive decisions across nursing, caregiving, and management functions.

1 investor

Fyodor Biosciences develops innovative diagnostics, medicines, and healthcare solutions with a focus on accessible global health. The company is led by scientists and health leaders with expertise in biomedical research and biotechnology.

1 investor

Fziomed develops proprietary dual-polymer gel technology for use across multiple surgical applications. The company focuses on providing innovative solutions for surgical procedures.

1 investor

GLNK provides healthcare data intelligence for life sciences organizations, offering profiles of healthcare providers, institutional data, payments tracking, medical device utilization metrics, and prescribing patterns across the US healthcare ecosystem.

1 investor

Gabar (Gabarx) is a biopharmaceutical company developing small-molecule drug candidates for central nervous system disorders such as anxiety and depression, drawing on deuterium-modified molecule chemistry. Its work spans clinical development, regulatory strategy, and CMC/quality across multiple therapeutic indications.

1 investor

Gaia Learning provides online learning services for children aged 8-16 with SEND (special educational needs and disabilities), delivered through 1:1 and group sessions. The company uses its proprietary Bloom platform to enable real-time progress tracking for parents, schools, and local authorities.

1 investor

Gaine provides a data architecture layer that prepares enterprise data for AI models by adding context, governance, and connection, then ensures AI decisions are executed back into operational systems with traceability.

1 investor

Gainwell Technologies provides a claims, encounters, and financials platform designed to help state Medicaid programs modernize their operations while reducing costs and improving accuracy. The company serves state Medicaid agencies and focuses on compliance with federal CMS mandates including AI integration and interoperability requirements.

1 investor

Galam is a global company that develops and produces raw materials, flavors, and food additives for food and beverage manufacturers, pet food producers, and industrial applications. Operating through two divisions—one focused on innovative food technology solutions including sugar reduction and fiber enrichment, and another producing starches, syrups, and specialty ingredients—the company serves thousands of customers across over 60 countries.

1 investor

Galen AI develops a mobile health application that aggregates medical records from healthcare providers and wearable devices, then uses AI to provide personalized health insights and recommendations for patients managing multiple conditions.

1 investor

Galen Clinic is a premium healthcare clinic serving both adults and children, offering family-doctor-style diagnostics and individualized treatment for entire families.

1 investor

Galen builds causal, computational models of living cells ("virtual cells") that aim to predict how a cell changes under a given intervention before experiments are run. Its initial focus is durability and exhaustion in engineered T cell therapies, serving scientists and drug developers working on cell therapies.

1 investor

Galenica distributes Leica confocal microscopes for biomedical research, enabling high-precision imaging of subcellular structures and dynamic cellular processes at nanoscopic resolution.

1 investor

Galenio provides a translation application designed for hospitals to communicate with foreign patients in over 200 languages, addressing language barriers during healthcare encounters. The platform supports doctors and patients through text and voice translation, form management, and conversation logging integrated with hospital systems.

1 investor

Inventum Biotech develops software solutions for analytical, multimodal, and AI-based applications focused on preventing and managing non-communicable diseases using data and analytics.

1 investor

Galvanize Therapeutics develops surgical ablation technology using its proprietary Aliya Pulsed Electric Field (PEF) energy to destroy soft tissue cells through regulated cell death mechanisms. Its products serve clinical fields such as interventional pulmonology and thoracic surgery.

1 investor

Galventa develops delivery technologies for food supplements and over-the-counter products designed to optimize dosage timing and bioavailability. The company focuses on improving the efficacy of nutraceutical formulations through galenic innovation.

1 investor

GAMGEE develops personalised mRNA cancer vaccines for dogs, created from the animal's own tumour tissue to help its immune system fight the cancer. The company manages the full process end to end—from diagnosis and tissue sampling with the pet owner's vet, to genomic analysis and treatment delivery via veterinary oncologists—and is currently running clinical trials in Australia while accepting applications globally.

1 investor

Gamida Cell develops cell therapy treatments designed to expand and enhance cells for therapeutic applications. The company focuses on delivering potentially curative therapies to patients with unmet medical needs.

1 investor

Gamma Diagnostics develops diagnostic tests based on Gamma Prime Fibrinogen (GPF), a blood biomarker for assessing inflammation and predicting cardiovascular and infectious disease outcomes. The company serves clinicians and healthcare providers seeking improved patient risk stratification and treatment planning.

1 investor

GammaTile is an FDA-cleared, bioresorbable collagen tile embedded with radiation sources that is implanted during brain tumor removal surgery to deliver targeted radiation to remaining cancer cells. It is indicated for patients with operable, newly diagnosed and recurrent brain tumors such as glioblastoma, brain metastases, and meningiomas.

1 investor

Gamow Labs builds an AI system that interprets whole genomes and clinical phenotypes to identify causative variants and produce ACMG-style clinical reports with auditable evidence and treatment recommendations. It serves clinical genetics workflows, focusing on genome interpretation and diagnosis of rare/hard cases.

1 investor

Gan & Lee appears to be a company with significant revenue (4.052 billion reported) and R&D investment activity (1.341 billion CNY), but the page visited does not contain clear information about its core business operations, products, or market focus.

1 investor

Garland Surgical develops the TriActiv Hip (formerly MaltaHip), a total hip replacement implant using a patented tri-axial design intended to improve mobility, stability, and durability while reducing revision surgeries. Aimed at orthopaedic surgeons and hip arthroplasty patients, the company plans to commercialize the device through OEM licensing, with an initial US market entry via FDA 510(k).

1 investor